FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580521753> ?p ?o ?g. }

• W2580521753 endingPage "424" @default.
• W2580521753 startingPage "418" @default.
• W2580521753 abstract "Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients.We performed a retrospective case-control study of B vs. W patients treated with AA between May 1, 2008 and June 16, 2015 at Duke University Medical Center. Patients were identified (W control patients were matched 2:1 to B patients stratified based on previous docetaxel exposure) through pharmacy records and were eligible if treated with AA for metastatic castration-resistant prostate cancer. Patients with previous enzalutamide use were excluded. The primary objective was to compare the rate of≥90% prostate-specific antigen (PSA) decline from baseline between B vs. W patients. Secondary outcomes included comparing time on therapy, time to PSA progression, and overall survival among groups.Baseline characteristics among patients (n = 45 B, n = 90 W) were identified; these included Karnofsky performance status, PSA, Gleason score, alkaline phosphatase, albumin, hemoglobin, lactate dehydrogenase, opiate use for pain, and metastatic sites. Baseline characteristics among groups were similar except for median hemoglobin (B = 11.4g/dl, W = 12.3g/dl). The proportion of B patients achieving a≥90% PSA level decline was 37.8% vs. 28.9% for W patients (P = 0.296). Statistically significant differences were found in the proportion of patients achieving a≥50% PSA level decline (B = 68.9%, W = 48.9% [P = 0.028]) and≥30% PSA level decline (B = 77.8%, W = 54.4% [P = 0.008]). Rates of primary abiraterone-refractory disease (PSA increase as best response) trended higher in W (31.1%) than in B (15.6%) patients (P = 0.052). Median treatment duration (B = 9.4 mo, W = 8.3 mo) did not differ (Wilcoxon P = 0.444). Median overall survival (B = 27.3 mo [95% CI: 13.9, not estimable], W = 24.8 mo [95% CI: 19, 31.6] [P = 0.669]) and median time to PSA progression (B = 11.0 mo [95% CI: 4.3, 18.0], W = 9.4 mo [95% CI: 6.2, 13.0] [P = 0.917]) did not differ.Black patients may have a higher PSA response to AA than white patients. An ongoing prospective clinical study (NCT01940276) is evaluating outcomes between black and white patients treated with AA." @default.
• W2580521753 created "2017-02-03" @default.
• W2580521753 creator A5000997350 @default.
• W2580521753 creator A5028554428 @default.
• W2580521753 creator A5033510051 @default.
• W2580521753 creator A5038489185 @default.
• W2580521753 creator A5040606607 @default.
• W2580521753 creator A5042656216 @default.
• W2580521753 creator A5047408345 @default.
• W2580521753 creator A5061888417 @default.
• W2580521753 creator A5071072809 @default.
• W2580521753 creator A5078940541 @default.
• W2580521753 date "2017-06-01" @default.
• W2580521753 modified "2023-10-02" @default.
• W2580521753 title "Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer" @default.
• W2580521753 cites W1968384034 @default.
• W2580521753 cites W2029180509 @default.
• W2580521753 cites W2033586061 @default.
• W2580521753 cites W2048462825 @default.
• W2580521753 cites W2110534364 @default.
• W2580521753 cites W2123098020 @default.
• W2580521753 cites W2134382692 @default.
• W2580521753 cites W2137467802 @default.
• W2580521753 cites W2145231286 @default.
• W2580521753 cites W2161817637 @default.
• W2580521753 cites W2167331614 @default.
• W2580521753 cites W2169941515 @default.
• W2580521753 cites W2278392405 @default.
• W2580521753 cites W2312818201 @default.
• W2580521753 cites W2403880768 @default.
• W2580521753 cites W2590552348 @default.
• W2580521753 doi "https://doi.org/10.1016/j.urolonc.2016.12.016" @default.
• W2580521753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28126272" @default.
• W2580521753 hasPublicationYear "2017" @default.
• W2580521753 type Work @default.
• W2580521753 sameAs 2580521753 @default.
• W2580521753 citedByCount "20" @default.
• W2580521753 countsByYear W25805217532018 @default.
• W2580521753 countsByYear W25805217532020 @default.
• W2580521753 countsByYear W25805217532021 @default.
• W2580521753 countsByYear W25805217532022 @default.
• W2580521753 countsByYear W25805217532023 @default.
• W2580521753 crossrefType "journal-article" @default.
• W2580521753 hasAuthorship W2580521753A5000997350 @default.
• W2580521753 hasAuthorship W2580521753A5028554428 @default.
• W2580521753 hasAuthorship W2580521753A5033510051 @default.
• W2580521753 hasAuthorship W2580521753A5038489185 @default.
• W2580521753 hasAuthorship W2580521753A5040606607 @default.
• W2580521753 hasAuthorship W2580521753A5042656216 @default.
• W2580521753 hasAuthorship W2580521753A5047408345 @default.
• W2580521753 hasAuthorship W2580521753A5061888417 @default.
• W2580521753 hasAuthorship W2580521753A5071072809 @default.
• W2580521753 hasAuthorship W2580521753A5078940541 @default.
• W2580521753 hasConcept C121608353 @default.
• W2580521753 hasConcept C126322002 @default.
• W2580521753 hasConcept C126894567 @default.
• W2580521753 hasConcept C143998085 @default.
• W2580521753 hasConcept C2775832370 @default.
• W2580521753 hasConcept C2776235491 @default.
• W2580521753 hasConcept C2776551883 @default.
• W2580521753 hasConcept C2777899217 @default.
• W2580521753 hasConcept C2780192828 @default.
• W2580521753 hasConcept C2781190966 @default.
• W2580521753 hasConcept C2781406297 @default.
• W2580521753 hasConcept C2908647359 @default.
• W2580521753 hasConcept C61367390 @default.
• W2580521753 hasConcept C71924100 @default.
• W2580521753 hasConcept C99454951 @default.
• W2580521753 hasConceptScore W2580521753C121608353 @default.
• W2580521753 hasConceptScore W2580521753C126322002 @default.
• W2580521753 hasConceptScore W2580521753C126894567 @default.
• W2580521753 hasConceptScore W2580521753C143998085 @default.
• W2580521753 hasConceptScore W2580521753C2775832370 @default.
• W2580521753 hasConceptScore W2580521753C2776235491 @default.
• W2580521753 hasConceptScore W2580521753C2776551883 @default.
• W2580521753 hasConceptScore W2580521753C2777899217 @default.
• W2580521753 hasConceptScore W2580521753C2780192828 @default.
• W2580521753 hasConceptScore W2580521753C2781190966 @default.
• W2580521753 hasConceptScore W2580521753C2781406297 @default.
• W2580521753 hasConceptScore W2580521753C2908647359 @default.
• W2580521753 hasConceptScore W2580521753C61367390 @default.
• W2580521753 hasConceptScore W2580521753C71924100 @default.
• W2580521753 hasConceptScore W2580521753C99454951 @default.
• W2580521753 hasIssue "6" @default.
• W2580521753 hasLocation W25805217531 @default.
• W2580521753 hasLocation W25805217532 @default.
• W2580521753 hasOpenAccess W2580521753 @default.
• W2580521753 hasPrimaryLocation W25805217531 @default.
• W2580521753 hasRelatedWork W1980998207 @default.
• W2580521753 hasRelatedWork W2263206436 @default.
• W2580521753 hasRelatedWork W2568045406 @default.
• W2580521753 hasRelatedWork W2768688864 @default.
• W2580521753 hasRelatedWork W2770702948 @default.
• W2580521753 hasRelatedWork W2776594178 @default.
• W2580521753 hasRelatedWork W3023947295 @default.
• W2580521753 hasRelatedWork W4205706045 @default.
• W2580521753 hasRelatedWork W4226040508 @default.
• W2580521753 hasRelatedWork W4229076799 @default.

• next